
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7974322/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction. European Journal of Medical Research, 2021, 26, 98.	0.9	16
2	Informed consent and informed intervention: SARS-CoV-2 vaccinations not just call for disclosure of newly emerging safety data but also for hypothesis generation and testing. European Journal of Medical Research, 2021, 26, 87.	0.9	1
3	Biophotonic pretreatment enhances the targeting of senile lentigines with a 694 nm QSâ€ruby laser. Photodermatology Photoimmunology and Photomedicine, 2020, 36, 159-160.	0.7	6
4	Long-term quality of life after preoperative radiochemotherapy in patients with localized and locally advanced breast cancer. Strahlentherapie Und Onkologie, 2020, 196, 386-397.	1.0	7
5	Dose- and time-dependent effects of hyaluronidase on structural cells and the extracellular matrix of the skin. European Journal of Medical Research, 2020, 25, 60.	0.9	9
6	Effective removal of solar lentigines by combination of pre– And post–fluorescent light energy treatment with picosecond laser treatment. Clinical Case Reports (discontinued), 2020, 8, 1429-1432.	0.2	4
7	EGFR/Ras-induced CCL20 production modulates the tumour microenvironment. British Journal of Cancer, 2020, 123, 942-954.	2.9	18
8	Long-term cosmetic outcome after preoperative radio-/chemotherapy in locally advanced breast cancer patients. Strahlentherapie Und Onkologie, 2019, 195, 615-628.	1.0	13
9	Adjuvant radiochemotherapy vs. chemotherapy alone in gastric cancer: aÂmeta-analysis. Strahlentherapie Und Onkologie, 2019, 195, 695-706.	1.0	8
10	Identification of facial vessels using Doppler ultrasound prior to cosmetic filler injection. JDDG - Journal of the German Society of Dermatology, 2019, 17, 1281-1282.	0.4	4
11	Clinical Applications of Hyaluronidase. Advances in Experimental Medicine and Biology, 2019, 1148, 255-277.	0.8	58
12	Time-lapse imaging points towards a non-toxic, mainly immune-driven mode of action of ingenol mebutate in the treatment of anogenital warts. Experimental Dermatology, 2018, 27, 675-677.	1.4	1
13	Ingenol mebutate induces a tumor cell-directed inflammatory response and antimicrobial peptides thereby promoting rapid tumor destruction and wound healing. European Journal of Medical Research, 2018, 23, 45.	0.9	7
14	Chemokine ligand–receptor interactions critically regulate cutaneous wound healing. European Journal of Medical Research, 2018, 23, 4.	0.9	35
15	Standardized in vitro analysis of the degradability of hyaluronic acid fillers by hyaluronidase. European Journal of Medical Research, 2018, 23, 37.	0.9	31
16	Brimonidine tartrate 0.33% gel for the management of posttreatment erythema induced by laser skin resurfacing. Journal of the American Academy of Dermatology, 2017, 76, e53-e55.	0.6	11
17	Ingenol mebutate for the management of genital warts in sensitive anatomic locations. Journal of the American Academy of Dermatology, 2017, 77, e9-e10.	0.6	8
18	A photoconverter gel-assisted blue light therapy for the treatment of rosacea. International Journal of Portage of Dermatology, 2017, 56, 1489-1490.	0.5	12

#	Article	IF	CITATIONS
19	Lesion intensified field therapy (<scp>LIFT</scp>): A new concept in the treatment of actinic field cancerization. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e232-e233.	1.3	4
20	Successful treatment of perianal condylomata acuminata with ingenol mebutate gel. JDDG - Journal of the German Society of Dermatology, 2016, 14, 616-617.	0.4	5
21	Erfolgreiche Behandlung von perianalen Condylomata acuminata mit Ingenolmebutat. JDDG - Journal of the German Society of Dermatology, 2016, 14, 616-617.	0.4	3
22	Topical brimonidine tartrate 0·33% gel effectively reduces the postâ€ŧreatment erythema of daylightâ€∎ctivated photodynamic therapy. British Journal of Dermatology, 2016, 174, 1422-1423.	1.4	7
23	Laserâ€essisted drug delivery: mode of action and use in daily clinical practice. JDDG - Journal of the German Society of Dermatology, 2016, 14, 480-488.	0.4	15
24	Laser assisted Drug Delivery: Grundlagen und Praxis. JDDG - Journal of the German Society of Dermatology, 2016, 14, 480-489.	0.4	3
25	Hyaluronidase: from clinical applications to molecular and cellular mechanisms. European Journal of Medical Research, 2016, 21, 5.	0.9	156
26	Mechanisms of skin aging induced by EGFR inhibitors. Supportive Care in Cancer, 2016, 24, 4241-4248.	1.0	26
27	Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials. Radiotherapy and Oncology, 2016, 118, 238-243.	0.3	91
28	Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features. Journal of Clinical and Aesthetic Dermatology, 2016, 9, 30-9.	0.1	16
29	Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials- an update. Radiation Oncology, 2015, 10, 258.	1.2	98
30	Laser-assisted drug delivery: Enhanced response to ingenol mebutate after ablative fractional laser treatment. Journal of the American Academy of Dermatology, 2015, 72, 364-365.	0.6	19
31	Effects of Radiotherapy in the treatment of multiple myeloma: a retrospective analysis of a Single Institution. Radiation Oncology, 2015, 10, 71.	1.2	26
32	METEORIN-LIKE is a cytokine associated with barrier tissues and alternatively activated macrophages. Clinical Immunology, 2015, 156, 119-127.	1.4	92
33	Severe hyperpigmentation and scarring following glycolic acid peel treatment in combination with low-dose isotretinoin. European Journal of Medical Research, 2014, 19, 60.	0.9	14
34	Hyaluronidase injection for the treatment of eyelid edema: a retrospective analysis of 20 patients. European Journal of Medical Research, 2014, 19, 30.	0.9	43
35	Severe everolimus-induced steatohepatis: a case report. European Journal of Medical Research, 2013, 18, 22.	0.9	12
36	Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck. Strahlentherapie Und Onkologie, 2013, 189, 625-631.	1.0	11

#	Article	IF	CITATIONS
37	Is the covering of the resection margin after distal pancreatectomy advantageous?. European Journal of Medical Research, 2013, 18, 33.	0.9	6
38	Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation. Science Translational Medicine, 2013, 5, 199ra111.	5.8	197
39	Systematic Identification and Characterization of Novel Human Skin-Associated Genes Encoding Membrane and Secreted Proteins. PLoS ONE, 2013, 8, e63949.	1.1	30
40	Herpetic whitlow. Cmaj, 2012, 184, E924-E924.	0.9	4
41	Long-term outcome after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer and predictive factors for a pathologic complete remission. Strahlentherapie Und Onkologie, 2012, 188, 777-781.	1.0	32
42	Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. European Journal of Medical Research, 2012, 17, 4.	0.9	20
43	Pitfalls in radiation oncology. Strahlentherapie Und Onkologie, 2012, 188, 359-362.	1.0	4
44	Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers. JDDG - Journal of the German Society of Dermatology, 2012, 10, 559-562.	0.4	6
45	Eskalationstherapie kutaner Nebenwirkungen von EGFR-Inhibitoren: Erfahrungen deutscher Referenzzentren. JDDG - Journal of the German Society of Dermatology, 2012, 10, 559-563.	0.4	6
46	Do insulin-like growth factor associated proteins qualify as a tumor marker? results of a prospective study in 163 cancer patients*. European Journal of Medical Research, 2011, 16, 451.	0.9	21
47	Aprotinin and classic wound drainage are unnecessary in total hip replacement a prospective randomized trial. European Journal of Medical Research, 2011, 16, 20.	0.9	4
48	The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract. European Journal of Medical Research, 2011, 16, 265.	0.9	19
49	Trimodal therapy in squamous cell carcinoma of the esophagus. European Journal of Medical Research, 2011, 16, 437.	0.9	5
50	Sunitinib induced pyoderma gangrenosum-like ulcerations. European Journal of Medical Research, 2011, 16, 491.	0.9	26
51	Density of <i>Demodex folliculorum</i> in Patients Receiving Epidermal Growth Factor Receptor Inhibitors. Dermatology, 2011, 222, 144-147.	0.9	56
52	Rosacea: the Cytokine and Chemokine Network. Journal of Investigative Dermatology Symposium Proceedings, 2011, 15, 40-47.	0.8	126
53	Hypopigmented scar formation after application of over-the-counter wart and mole removal cream. Wiener Klinische Wochenschrift, 2011, 123, 183-185.	1.0	1
54	Bevacizumab as a Treatment Option for Radiation-Induced Cerebral Necrosis. Strahlentherapie Und Onkologie, 2011, 187, 135-139.	1.0	79

#	Article	IF	CITATIONS
55	Cystatin C – A Fast and Reliable Biomarker for Glomerular Filtration Rate in Head and Neck Cancer Patients. Strahlentherapie Und Onkologie, 2011, 187, 191-201.	1.0	24
56	More on Aprepitant for Erlotinib-Induced Pruritus. New England Journal of Medicine, 2011, 364, 486-487.	13.9	51
57	Pyoderma gangrenosum associated with chronic polyarthritis: Figure 1:. Cmaj, 2011, 183, 1746-1746.	0.9	5
58	Evaluation of the tissue toxicity of antiseptics by the hen's egg test on the chorioallantoic membrane (HETCAM). European Journal of Medical Research, 2010, 15, 204.	0.9	24
59	Identification of candidate genes with pro-apoptotic properties by functional screening of randomly fragmented CDNA libraries. European Journal of Medical Research, 2010, 15, 162.	0.9	2
60	Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease. European Journal of Medical Research, 2010, 15, 277-86.	0.9	49
61	Pyoderma gangrenosum. Wiener Klinische Wochenschrift, 2010, 122, 75-75.	1.0	2
62	Basal cell carcinoma. Wiener Klinische Wochenschrift, 2010, 122, 219-219.	1.0	1
63	Allergy â€~sucks': Leeches may also be harmful. Contact Dermatitis, 2010, 62, 124-125.	0.8	4
64	Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor–induced pruritus. Journal of the American Academy of Dermatology, 2010, 63, 163-165.	0.6	39
65	Chemokines in tumor-associated angiogenesis. Biological Chemistry, 2009, 390, 1213-1223.	1.2	60
66	Bortezomib induces erythema multiforme-like cutaneous adverse effects: report of two cases. Wiener Klinische Wochenschrift, 2009, 121, 723-724.	1.0	7
67	Leser-Trélat sign presenting in a patient with ovarian cancer: a case report. Journal of Medical Case Reports, 2009, 3, 8583.	0.4	6
68	Neurofibromatosis. European Journal of Medical Research, 2009, 14, 102-5.	0.9	55
69	Current concepts in stereotactic radiosurgery - a neurosurgical and radiooncological point of view. European Journal of Medical Research, 2009, 14, 93.	0.9	27
70	Gene expression of circulating tumour cells in breast cancer patients. European Journal of Medical Research, 2009, 14, 426-32.	0.9	11
71	Correlation of cutaneous tension distribution and tissue oxygenation with acute external tissue expansion. European Journal of Medical Research, 2009, 14, 480-6.	0.9	7
72	Chest wall and intrathoracic desmoid tumors: surgical experience and review of the literature. European Journal of Medical Research, 2009, 14, 240.	0.9	26

#	Article	IF	CITATIONS
73	Gene expression of circulating tumour cells and its correlation with tumour stage in breast cancer patients. European Journal of Medical Research, 2009, 14, 359-63.	0.9	11
74	Kutane Nebenwirkungen unter Therapie mit EGFR-Inhibitoren. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2009, , 248-251.	0.0	0
75	Development and Management of Severe Cutaneous Side Effects in Head-and-Neck Cancer Patients during Concurrent Radiotherapy and Cetuximab. Strahlentherapie Und Onkologie, 2008, 184, 105-110.	1.0	64
76	Chloromas. Wiener Klinische Wochenschrift, 2008, 120, 209-209.	1.0	0
77	Soft tissue sarcoma. Wiener Klinische Wochenschrift, 2008, 120, 732-732.	1.0	0
78	Blonde by prescription. Arthritis and Rheumatism, 2008, 58, 2286-2286.	6.7	12
79	Pregnancy after laser-assisted selection of viable spermatozoa before intracytoplasmatic sperm injection in a couple with male primary cilia dyskinesia. Fertility and Sterility, 2008, 89, 1826.e9-1826.e12.	0.5	34
80	The dire consequences of doping. Lancet, The, 2008, 372, 656.	6.3	16
81	Eccrine Porocarcinoma of the Head: An Important Differential Diagnosis in the Elderly Patient. Dermatology, 2008, 216, 229-233.	0.9	20
82	The Koebner-Phenomenon in Epidermal Growth Factor Receptor Inhibitor–Induced Cutaneous Adverse Effects. Journal of Clinical Oncology, 2008, 26, 2790-2792.	0.8	22
83	Skin-Sparing Intensity-Modulated Radiotherapy of the Breast. Journal of Clinical Oncology, 2008, 26, 5305-5306.	0.8	1
84	Erlotinib-Induced Hair Alterations. New England Journal of Medicine, 2008, 358, 1175-1175.	13.9	16
85	Tumor immune escape by the loss of homeostatic chemokine expression. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19055-19060.	3.3	125
86	Radiation-Induced Prevention of Erlotinib-Induced Skin Rash Is Transient: A New Aspect Toward the Understanding of Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Adverse Effects. Journal of Clinical Oncology, 2007, 25, 4697-4698.	0.8	19
87	Chemokine receptors in head and neck cancer: Association with metastatic spread and regulation during chemotherapy. International Journal of Cancer, 2006, 118, 2147-2157.	2.3	91
88	Doxorubicin induces EGF receptor-dependent downregulation of gap junctional intercellular communication in rat liver epithelial cells. Biological Chemistry, 2005, 386, 217-223.	1.2	25
89	Epidermal Growth Factor Receptor Is a Common Mediator of Quinone-induced Signaling Leading to Phosphorylation of Connexin-43. Journal of Biological Chemistry, 2003, 278, 38360-38367.	1.6	102